Weekly Cardiology Research Analysis
This week’s cardiology literature highlights three high-impact themes: diagnostic gaps in HFpEF where the 2025 ASE diastolic algorithm shows poor sensitivity against invasive hemodynamics; a translational cardio‑oncology signal demonstrating that left‑ventricular pressure overload creates a metabolic vulnerability that markedly increases anthracycline cardiotoxicity and points to energetics‑modulating prevention strategies; and long-term randomized evidence (FAME 2) that physiology‑guided (FFR)
Summary
This week’s cardiology literature highlights three high-impact themes: diagnostic gaps in HFpEF where the 2025 ASE diastolic algorithm shows poor sensitivity against invasive hemodynamics; a translational cardio‑oncology signal demonstrating that left‑ventricular pressure overload creates a metabolic vulnerability that markedly increases anthracycline cardiotoxicity and points to energetics‑modulating prevention strategies; and long-term randomized evidence (FAME 2) that physiology‑guided (FFR) revascularization yields durable composite benefits driven by fewer urgent revascularizations. These findings span immediate diagnostic practice implications, a testable preventive paradigm in cardio‑oncology, and reaffirmed benefits of physiology-guided revascularization.
Selected Articles
1. Echocardiographic Diastolic Function Grading in HFpEF: Testing the Updated 2025 ASE Criteria.
In cohorts with invasively confirmed HFpEF, the 2025 ASE diastolic grading algorithm frequently classified patients as normal or Grade 1 despite elevated filling pressures; stress criteria detected only a minority of cases and overall discrimination versus noncardiac dyspnea was poor (AUC 0.61). The study underscores that echocardiographic diastolic grades cannot be used in isolation to exclude HFpEF and should be interpreted with pretest probability and invasive hemodynamics when needed.
Impact: Challenges a newly promoted echocardiographic standard by demonstrating high false‑negative rates versus invasive hemodynamics, with direct implications for diagnostic pathways and guideline implementation.
Clinical Implications: Clinicians should not rely solely on the 2025 ASE diastolic grading to exclude HFpEF. Use clinical pretest probability, consider invasive hemodynamics or HFpEF‑specific diagnostic algorithms, and prioritize further testing when suspicion remains.
Key Findings
- 67.6% of ambulatory HFpEF patients were labeled normal or Grade 1, yet >60% of those had resting PAWP ≥15 mm Hg.
- ASE-recommended stress criteria identified only 9.5% of Grade 1 HFpEF during hemodynamic exercise testing (90.5% false‑negative rate).
- Algorithm discrimination versus noncardiac dyspnea was poor (AUC 0.61); patients labeled normal/Grade 1 still had high event risk.
2. Anthracycline cardiotoxicity: role of metabolic vulnerability induced by cardiac pressure overload.
In a porcine model, pre‑existing left ventricular pressure overload produced a high‑energy‑demand myocardial state that rendered the heart highly susceptible to otherwise low‑risk doses of doxorubicin, causing increased mortality, LV dysfunction, fibrosis, and mitochondrial respiratory impairment. Reducing energy demand with mavacamten rescued cardiomyocyte viability in cell models, pointing to energetics modulation as a preventive strategy.
Impact: Provides a mechanistic, translational link between common clinical LV pressure overload states (hypertension, valvular disease) and anthracycline cardiotoxicity, identifying myocardial energetics as a targetable vulnerability with clear translational implications for cardio‑oncology care.
Clinical Implications: Patients with LV pressure overload who will receive anthracyclines should be considered for intensified cardio‑oncology assessment, optimized blood pressure/valve management, and testing of energetics‑modulating preventive interventions in trials.
Key Findings
- Pressure overload plus low‑dose doxorubicin led to increased mortality, LVEF reduction, fibrosis, and impaired mitochondrial respiration in pigs.
- Pressure overload induced compensatory metabolic remodeling (e.g., reduced phosphocreatine) that predisposed to anthracycline injury.
- Mavacamten reduced energetic demand and rescued cardiomyocyte viability under combined hypertrophic and doxorubicin stress in vitro.
3. Fractional flow reserve-guided percutaneous coronary intervention versus medical therapy for stable coronary artery disease: long-term results of the FAME 2 trial.
Extended follow‑up (median 11.2 years) of the FAME 2 randomized trial demonstrated that FFR‑guided PCI in patients with hemodynamically significant lesions (FFR ≤0.80) reduced the composite of death, MI, or urgent revascularization versus medical therapy alone, largely driven by a marked reduction in urgent revascularizations. Mortality was similar between groups, and the durable benefit supports physiology‑guided revascularization in selected stable CAD patients.
Impact: Provides long‑term randomized evidence reaffirming the clinical value of physiology‑guided (FFR) revascularization in stable CAD, informing shared decision‑making and guideline considerations.
Clinical Implications: For patients with FFR‑positive lesions, discuss sustained benefit of revascularization (primarily fewer urgent procedures) versus medical therapy; integrate symptom burden, ischemic testing, and patient preference into shared decisions.
Key Findings
- Median 11.2‑year follow‑up: primary composite occurred in 33.6% (PCI) vs 41.3% (medical), win ratio 1.25 favoring PCI (P=0.043).
- Benefit driven largely by fewer urgent revascularizations (win ratio 4.57); all‑cause mortality was similar.
- Number needed to treat for the win difference estimated at 17 (95% CI 9–500).